Technology
Health
Biotechnology

Armata Pharmaceuticals

$3.45
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.67 (24.10%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ARMP and other stocks, options, ETFs, and crypto commission-free!

About

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. Read More The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.

Employees
31
Headquarters
Los Angeles, California
Founded
2019
Market Cap
6.51M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
51.13K
High Today
$3.45
Low Today
$3.03
Open Price
$3.04
Volume
28.71K
52 Week High
$19.18
52 Week Low
$2.15

Collections

Technology
Health
Biotechnology
US
North America

News

Seeking AlphaMay 28

ARMP, BIOC among top gainers

Armata Pharmaceuticals (NYSEMKT:ARMP) +28% on encouraging AP-PA01 data. Biocept (NASDAQ:BIOC) +24% on being awarded Chinese Patent No. ZL201080019566.9 entitled, devices and methods of cell capture and analysis. The9 (NASDAQ:NCTY) +17% on signing a joint venture agreement (the "JV agreement") with Shenzhen EN-plus Technologies. Eldorado Gold (NYSE:EGO) +14% on optimism over Greek snap election. Anaplan (NYSE:PLAN) +12% on Q1 earnings. Jumei International Holding (NYSE:JMEI) +12% on share repurchase. S...

4,486

Earnings

Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.